Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

NCT05990374 · Unknown status

Last updated 2026-05-28

This clinical trial studied how GLP-1 receptor agonists affect blood sugar levels and body fat in adults with type 2 diabetes over a period of 1 to 4 years.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 100 people Planned (estimated).

Who can join all sexes

Timeline Started 2023-08 · est. completion 2024-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05990374 ↗

Description as written by the study sponsor.

The efficacy of long-term treatment with different GLP-1RA (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc.) was evaluated through 1-4 years of follow-up, and the effects of long-term treatment on blood glucose and body fat of patients.

Treatments tested

Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc Drug

The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.

Main thing measured	Effects of different GLP-1 on blood glucose
Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions studied	Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05990374 ↗